Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
74 results about "Diabetes insipidus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A condition that results from an imbalance of water in the body.
Methods and devices for desmopressin drug delivery
InactiveUS20090042970A1Reduce urine productionRestore normal urine productionBiocidePowder deliveryDecreased sodiumSide effect
Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.
Owner:SERENITY PHARMA CORP
4,4-Difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
InactiveUS20050004103A1Increase irritationEffective diagnosisBiocideOrganic chemistryArgininePharmacology
4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives, which have excellent arginine vasopressin V2 activity and are useful for a drug for the treatment of central diabetes insipidus and / or nocturia.
Owner:ASTELLAS PHARMA INC
Pharmaceutical formulations
ActiveUS20050232997A1Improve bioavailabilityPowder deliveryMetabolism disorderWater dispersibleWater soluble
Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
Owner:FERRING BV
Condensed azepines as vasopressin agonists
This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are =O, -O(CH2)pO- or -S(CH2)pS-; W1 is either O or S; X1 and X2 are both H, or together are =O or =S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are -(CH2)n; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.
Owner:VANTIA
Condensed azepines as vasopressin agonists
This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ═O, —O(CH2)pO— or —S(CH2)pS—; W1 is either O or S; X1 and X2 are both H, or together are ═O or ═S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n—; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.
Owner:VANTIA
4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof
ActiveUS20060122170A1Good effectReduced inhibitory activityBiocideOrganic chemistryDiabetes insipidusNocturnal polyuria
A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and / or diabetes insipidus, is provided.
Owner:TACURION
Benzimidazole derivatives
InactiveUS7125877B2High selectivityExcellent antagonismGroup 4/14 element organic compoundsBiocideBenzimidazole derivativeHypotension shock
This invention provides compounds which are represented by a general formula [I][in which X stands for hydrogen or halogen; B stands for halogen, cyano or optionally fluorine-substituted lower alkyl; D stands for a 3–10 membered aliphatic nitrogen-containing heterocyclic group; R3, R4 and R5 may be same or different, and each stands for hydrogen, lower alkyl optionally having substituent group(s) and the like; and a is 0 or 1]. These compounds exhibit high affinity to nociceptin receptors and whereby inhibit actions of nociceptin, and are useful as an analgesic, antiobestic, agent for ameliorating brain function, treating agents for Alzheimer's disease and dementia, and therapeutic agents for schizophrenia, neurodegenerative diseases, depression, diabetes insipidus, polyuria, hypotension and the like.
Owner:MSD KK
Condensed azepines as vasopressin agonists
This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ═O, —O(CH2)pO— or —S(CH2)pS—; W1 is either O or S; X1 and X2 are both H, or together are ═O or ═S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.
Owner:VANTIA
Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles
The present invention is directed to 1,2,3,4,10,10a,-hexahydro-pyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R<1 >to R<8 >have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
![Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles](https://images-eureka.patsnap.com/patent_img/f2819470-6201-4ba2-aeb0-f25011f768ec/US20030216401A1-20031120-C00001.png "Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles")
![Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles](https://images-eureka.patsnap.com/patent_img/f2819470-6201-4ba2-aeb0-f25011f768ec/US20030216401A1-20031120-C00002.png "Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles")
![Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles](https://images-eureka.patsnap.com/patent_img/f2819470-6201-4ba2-aeb0-f25011f768ec/US20030216401A1-20031120-C00003.png "Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles")
Owner:VERNALIS RES +1
Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both
A present invention provides aromatic amide derivatives which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like, and are represented by the general formula (I): wherein R1 represents a hydrogen atom or a C1-6 alkyl group which may have a substituent, R2 is a hydrogen atom or a C1-6 alkyl group, R3 is a hydrogen atom, a C1-6 alkyl group or the like, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, R7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C3-8 cycloalkyl group, an amino group which may have a substituent or a C1-6 alkoxy group which may have a substituted group; M1 is a single bond, a C1-4 alkylene group or the like Y is N or CRF (in the formula, RF represents a hydrogen atom, a C1-6 alkyl group or the like or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.
Owner:KISSEI PHARMA
Methods and devices for desmopressin drug delivery
InactiveUS8399410B2Prevent adverse side effectsReduce productionElectrotherapyMicroneedlesDecreased sodiumSide effect
Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.
Owner:SERENITY PHARMA CORP
Safe Desmopressin Administration
ActiveUS20120149643A1Extended maintenance periodReduce riskNervous disorderPeptide/protein ingredientsDiseaseBacteriuria
Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.
Owner:ACERUS PHARM USA LLC
Safe desmopressin administration
ActiveUS9539302B2Reduce riskSufficient amountNervous disorderPeptide/protein ingredientsDiseaseHuman patient
Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.
Owner:ACERUS PHARM USA LLC
Desmopressin composition
InactiveUS20100160214A1Consistent and time limited durationNarrow downAntibacterial agentsBiocideDiseasePrimary nocturnal enuresis
Disclosed is a pharmaceutical formulation that may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.
Owner:ALLERGAN INC
Peptide formulations and uses thereof
InactiveCN102209553APeptide/protein ingredientsMetabolism disorderVasopressin preparationOxytocin preparation
The present invention relates to the field of preventive and therapeutic medicine, in particular to peptide formulations. Provided is a p H-buffered aqueous formulation comprising oxytocin, vasopressin or an analogue thereof and at least one non-toxic source of divalent metal ions in a concentration of at least 2 m M, and the use of the formulation for the manufacture of a medicament for therapeutic and / or prophylactic treatments. Also provided is a method for treating or preventing haemorrhage in a subject in need thereof, comprising administering to said subject an effective dosage amount of an oxytocin formulation according to the invention. Further provided is a method for treating or preventing diabetes insipidus or vasodilatory shock in a subject in need thereof, comprising administering to said subject an effective dosage amount of a vasopressin formulation according to the invention.
Owner:UNIVERSITY OF GRONINGEN
Use of a compound for enhancing the expression of membrane proteins on the cell surface
InactiveUS20090017006A1Increased cell mortalityHigh expressionOrganic active ingredientsDipeptide ingredientsDiseaseMedicine
The present invention is directed to the use of Bortezomib and / or a pharmaceutically acceptable salt or ester thereof for the manufacture of a medicament for enhancing the expression of membrane proteins on the cell surface. Especially, the invention is directed to the use of Bortezomib for the manufacture of a medicament for the treatment of a disease of condition selected from the group consisting of cystic fibrosis, diabetes insipidus, hypercholesterinaemia and long QT-syndrome-2.
Owner:AXENTIS PHARMA
Oral administration traditional Chinese medicine composition for treating diabetes insipidus
InactiveCN101085290ADecreased water intakeSpirit as usualAnthropod material medical ingredientsBlood disorderOral medicationPollen
The invention discloses an oral administration pharmaceutical composition for treating diabetes insipidus, which is a decoction prepared from the following raw materials through grilling with water: gorgon euryale seed 16g, prepared rhizome of rehmannia 25g, pulp of dogwood fruit 12g, Chinese yam 25g, poria cocos wolf 25g, oriental water plantain rhizome 12g, astragalus root 35g, doddor seed 12g, root of Chinese trichosannthes 16g, ichih fruit 9g, ootheca rubra 16g, cherokee rose 16g, raspberry 16g and gingko leaf 16g.
Owner:崔淑云 +2
Use Of A Compound For Enhancing The Expression Of Membrane Proteins On The Cell Surface
InactiveUS20100129343A1High expressionLower Level RequirementsOrganic active ingredientsSugar derivativesDiseaseIntegral membrane protein
Owner:AXENTIS PHARMA
4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives or salts thereof
4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives, which have excellent arginine vasopressin V2 activity and are useful for a drug for the treatment of central diabetes insipidus and / or nocturia.
Owner:ASTELLAS PHARMA INC
Compositions and methods for the treatment of metabolic syndrome
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hyperuricemia, gout; dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications,.macrovascular complications, lipid disorders, prediabetes., obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, and post prandial hyperglycemia.
Owner:CELLIXBIO PTE LTD
Traditional Chinese medicine preparation with oral administration for treating diabetes insipidus
InactiveCN102366514ARelieve symptomsNo side effectsBlood disorderExtracellular fluid disorderOral medicationCodonopsis pilosula
The invention provides a traditional Chinese medicine preparation with oral administration for treating diabetes insipidus, which contains the following components calculated according to parts by weight: 7 to 11 of tuckahoe, 7 to 11 of polyporus umbellatus, 7 to 11 of rhizoma atractylodis macrocephalae, 7 to 11 of rhizoma alismatis, 7 to 11 of cassia twig, 9 to 15 of radix codonopsis pilosulae, 9 to 15 of Adenophora stricta and 9 to 15 of Chinese yam. Compared with the prior art, the traditional Chinese medicine preparation with the oral administration for treating the diabetes insipidus, which aims at the comprehensive pathogenic factor of the diabetes insipidus, carries out diagnosis and treatment based on the overall analysis of an illness and the condition of a patient. The traditional Chinese medicine preparation with the oral administration for treating the diabetes insipidus has a good effect and low recurrence rate and addresses both the symptoms and root causes, and the ailment of the patient is effectively relieved.
Owner:CHENGDU LYUDI TECH
Traditional Chinese medicine for treating central diabetes insipidus
InactiveCN104161867AEffective treatmentSimple recipeBlood disorderExtracellular fluid disorderSide effectCurative effect
The invention belongs to a traditional Chinese medicine and discloses a traditional Chinese medicine for treating central diabetes insipidus. The traditional Chinese medicine for treating central diabetes insipidus comprises 8-12g of radix glehniae, 8-12g of cortex phellodendri and 8-12g of licorice root. The traditional Chinese medicine is designed according to theory of syndrome differentiation of traditional Chinese medicine, has a simple formula, is prepared from easily available materials, has a low cost and high curative effects, has no toxic or side effect, and can effectively treat central diabetes insipidus.
Owner:李立群
Traditional Chinese medicine for curing diabetes insipidus
InactiveCN101579461ANo adverse reactionHas a therapeutic effectAnthropod material medical ingredientsBlood disorderSide effectRegimen
The invention relates to a traditional Chinese medicine for curing diabetes insipidus. The traditional Chinese medicine is characterized by mainly comprising the following Chinese medical herbs: 10 g of wolferry fruit, 10 g glossy privet fruit, 10 g Korean raspberry, 10 g Chinese dodder, 6 g of magnolia vine fruit, 12 g of crude radix dioscoreae, 15 g of prepared rehmannia root, 6 g of achyranthes root, 10 g of bupleurum root, 9 g of pulp of dogwood fruit, 10 g of Erdong, 6 g of Zhibai, 12 g of calcined oyster shell and 10 g of mantis egg-case. The preparation method of the traditional Chinese medicine comprises the following steps: the Chinese medical herbs are put in a vessel to be soaked with water for 30 minutes, boiled with mild fire for 30 minutes and then filtered to obtain 150 ml of decoction, and the decoction is taken after supper and by one dose per day; and 5 dosages are taken as one period of treatment. The preparation is prepared from the pure Chinese medical herbs by a traditional preparation method, and the traditional Chinese medicine retains the medicinal properties, has the effects of enriching yin, tonifying kidney and stopping metrorrhagia, achieves the purpose of curing the diabetes insipidus and has no side effect.
Owner:尚爱永
4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzoazepine derivative or salt of the same
The present invention provides a novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which can be used as a therapeutic Or an agent for the prevention of nocturnal frequency and / or diabetes insipidus.
Owner:ASTELLAS PHARMA INC
Traditional Chinese medicine decoction for treating diabetes insipidus
InactiveCN103656273ASignificant effectImprove efficiencyAnthropod material medical ingredientsBlood disorderCodonopsis pilosulaPollen
Owner:杨莉
Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellullar senescence produced by diabetis and other degenerative chronic complex diseases
ActiveUS20160354331A1Hydroxy compound active ingredientsMetabolism disorderLipid formationAcute hyperglycaemia
The invention relates to compounds of natural origin and their pharmaceutically acceptable and active mixture to decrease glucose, cholesterol, uric acid, and body fat the high levels, cytoprotection of damaged organs, activation of metabolism and cell proliferation. It is exemplified with the pharmaceutical composition comprising a pharmaceutically effective amount of the compounds of Formulation I, and its method on in vitro and in vivo systems. Formulation I and its variables can be used to treat hyperglycemia, gout, dyslipidemia, obesity, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, pre-diabetes, arrhythmias, myocardial infarction, renal and pancreatic complications, cardiovascular complications.
Owner:ASTUDILLO DE LA VEGA HORACIO
Traditional Chinese medicine for treating diabetes insipidus
InactiveCN102366550ARelieve symptomsNo side effectsAluminium/calcium/magnesium active ingredientsEndocrine system disorderDiseaseMedicine
The invention provides a traditional Chinese medicine for treating diabetes insipidus. The traditional Chinese medicine for treating diabetes insipidus comprises: by weight, 28 to 32 parts of gypsum, 7 to 11 parts of rhizoma anemarrhenae, 12 to 18 parts of radix adenophorea, 12 to 18 parts of dwarf lilyturf tuber, 12 to 18 parts of dendrobium, 12 to 18 parts of mongolian snakegourd root, 12 to 18 parts of Chinese yam, 7 to 11 parts of cornus officinalis and 2 to 4 parts of licorice. Compared with the prior art, the traditional Chinese medicine for treating diabetes insipidus aims at a comprehensive pathogenesis, realizes diagnosis and treatment based on an overall analysis of diseases and patient's conditions, has good effects and a low recurrence rate, can treat both principal and secondary aspects of a disease, and effectively releases patient's illness.
Owner:CHENGDU LYUDI TECH
Traditional Chinese medicine medicament for treating diabetes insipidus
InactiveCN104096078ASafe and effective treatmentNo significant differenceBlood disorderExtracellular fluid disorderMedicinal herbsSmoked Plum
The invention relates to a traditional Chinese medicine medicament for treating diabetes insipidus. The traditional Chinese medicine medicament for treating diabetes insipidus is prepared from the following medicines in parts by weight: 6-12 parts of smoked plum, 6-12 parts of medlar, 3-9 parts of pedicularis verticillata, 5-12 parts of radix paeoniae alba, 5-9 parts of cynomorium songaricum, 2-7 parts of maidenhair spleenwort, 1-3 parts of folia perillae acutae, 3-9 parts of blackend swallowwort root, 9-15 parts of canthopanax obovatus hoo, 3-6 parts of eucommia ulmoides, 2-6 parts of glossy privet fruit, 10-20 parts of rhus chinensis mill, 9-15 parts of poria cocos, 6-12 parts of fraxinus pennsylvanica, 9-15 parts of teasel root, 5-10 parts of siberian nitraria fruit, 4-12 parts of pyrrosia martini, 12-30 parts of rehmannia, 3-5 parts of pollen pini, 3-9 parts of cordyceps sinensis, 2-8 parts of rhizome of fourleaf paris and 5-10 parts of trichosanthes palmate. Clinical experiments prove that the traditional Chinese medicine medicament for treating diabetes insipidus disclosed by the invention is capable of safely and effectively treating diabetes insipidus.
Owner:张相骋
Orally taken traditional Chinese medicine composition for treating diabetes insipidus
The invention discloses an oral administration pharmaceutical composition for treating diabetes insipidus, wherein the active constituents include the following raw material herbs (by weight portion): wolfberry fruit 10g, raspberry 10g, doddor seed 10g, schisandra fruit 6g, Chinese yam 12g, prepared rhizome of rehmannia 15g, pulp of dogwood fruit 9g, oyster 12g, ootheca rubra 10g, bitter cardamom 9g and poria cocos wolf 25g. The medicament should be decocted in water for the oral dose.
Owner:孙元萍
Traditional Chinese medicine composition for treating diabetes insipidus
InactiveCN102366515ARelieve symptomsNo side effectsBlood disorderExtracellular fluid disorderDiseaseAdditive ingredient
The invention provides a traditional Chinese medicine composition for treating diabetes insipidus, which comprises the following ingredients by weight part: 28-32 parts of gypsum, 7-11 parts of rhizoma anemarrhenae, 12-18 parts of root of straight ladybell, 12-18 parts of radix ophiopogonis, 12-18 parts of dendrobium, 12-18 parts of Chinese Trichosanthes, 12-18 parts of Chinese yam, 7-11 parts of fructus corni and 2-4 parts of licorice. Compared with the prior art, the traditional Chinese medicine composition aims at the syndrome of diabetes insipidus, is capable of performing therapies with syndrome differentiation, and has the advantages of good curative effect and low recurrence rate. The traditional Chinese medicine composition treats both principal and secondary aspect of disease and effectively releases the illness of the patient.
Owner:CHENGDU LYUDI TECH
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com